Mibolerone Analysis

The Mibolerone Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of mibolerone in oil-based samples, oral dosage forms, and raw active pharmaceutical ingredient (API) powders.

For oil-based samples, results are reported in mg/mL. For tablets and capsules, results are reported in mg per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).

About Mibolerone

Mibolerone is a synthetic, orally active anabolic-androgenic steroid, also known as dimethylnandrolone or 7α,17α-dimethyl-19-nortestosterone. It interacts with androgen receptors and exhibits strong androgenic and anabolic activity. The compound has also been studied for its progestogenic activity.

Mibolerone was developed for veterinary use and has been used to suppress oestrus in female dogs. It is distinct from methyltestosterone and methyl-1-testosterone despite belonging to the same broader class of synthetic androgenic steroids.

Key Features

• Targeted identification and quantification of mibolerone
• Suitable for oil-based samples, tablets, capsules, and raw API powders
• Analysis by HPLC
• Results for oil samples reported in mg/mL
• Results for oral products reported in mg per tablet or capsule
• Results for raw API powders reported as percentage content
• Optional purity reporting in % (m/m) for raw API powders
• Minimum sample amount of 0.5–1 mL for oil samples
• Minimum sample amount of three tablets or capsules
• Minimum sample amount of 200 mg for raw API powders
• Average turnaround time of 7 business days

Analysis Parameters

• Target compound: Mibolerone
• CAS number: 3704-09-4
• Molecular weight: 302.5 g/mol
• Testing method: HPLC
• Minimum concentration for evaluation in oil samples: 0.5 mg/mL
• Minimum amount for evaluation in oral products: 0.5 mg per pill, tablet, or capsule
• Minimum content for evaluation in raw API powders: 10%
• Result format for oil samples: mg/mL
• Result format for oral products: mg per tablet or capsule
• Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]
• Minimum sample amount for oil samples: 0.5–1 mL
• Minimum sample amount for oral products: Three tablets or capsules
• Minimum sample amount for raw API powders: 200 mg
• Average turnaround time: 7 business days

Important Notice

• This analysis is specifically intended for mibolerone. It does not automatically screen the sample for other anabolic steroids or undeclared substances.
• For oil samples, the minimum concentration of mibolerone for evaluation is 0.5 mg/mL. For oral products, the minimum amount is 0.5 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.
• Purity reporting in % (m/m) is available only for raw API powders.

Optional Additional Analyses

The following optional laboratory services are available:

• Complete Raw Analytical Data
• Alternative Result Format: Purity in % (m/m) - only for raw API powders
• Fentanyl Screening
• GC–MS Contamination Screening
• Heavy Metals Analysis (As, Cd, Pb, Hg)
• Additional Laboratory Report